{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T02:07:02Z","timestamp":1794967622269,"version":"4.9.1"},"reference-count":23,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Observational studies and stand-alone trials indicate that patients with follicular lymphoma (FL) who experience disease progression within 24 months of front-line chemoimmunotherapy (POD24), have poor outcomes. We performed a pooled analysis of 13 randomized clinical trials of patients with FL in the pre- and postrituximab eras to identify clinical factors that predict POD24. Logistic regression models evaluated the association between clinical factors and POD24. Cox regression evaluated the association between POD24 as a time-dependent factor and subsequent overall survival (OS). A landmark analysis evaluated the association of POD24 with OS for the subset of patients who were alive at 24 months after trial registration. Patients without progression at 24 months at baseline had favorable performance status (PS), limited-stage (I\/II) disease, low-risk FL International Prognostic Index (FLIPI) score, normal baseline hemoglobin, and normal baseline \u03b22 microglobulin (B2M) level. In a multivariable logistic regression model, male sex (odds ratio [OR], 1.30), PS \u22652 (OR, 1.63), B2M (\u22653 mg\/L; OR, 1.43), and high-risk FLIPI score (3-5; OR, 3.14) were associated with increased risk of progression before 24 months. In the time-dependent Cox model and the 24-month landmark analysis, POD24 was associated with poor subsequent OS (hazard ratio, 4.85 and 3.06, respectively). This is the largest pooled analysis of clinical trials data validating POD24 as a robust indicator of poor FL survival and identified clinical predictors of early death and progression that can aid in building comprehensive prognostic models incorporating clinical and molecular predictors of POD24.<\/jats:p>","DOI":"10.1182\/blood.2020010263","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T14:10:34Z","timestamp":1647526234000},"page":"1684-1693","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":172,"title":["Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials"],"prefix":"10.1182","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4998-9932","authenticated-orcid":false,"given":"Carla","family":"Casulo","sequence":"first","affiliation":[{"name":"Wilmot Cancer Institute, University of Rochester, Rochester, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse G.","family":"Dixon","sequence":"additional","affiliation":[{"name":"Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2234-7430","authenticated-orcid":false,"given":"Jennifer","family":"Le-Rademacher","sequence":"additional","affiliation":[{"name":"Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0749-1389","authenticated-orcid":false,"given":"Eva","family":"Hoster","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, Ludwig-Maximilians University Hospital, Campus Grosshadern, Munich, Germany; Division of Hematology-Oncology and Transplantation;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9893-1529","authenticated-orcid":false,"given":"Howard S.","family":"Hochster","sequence":"additional","affiliation":[{"name":"Rutgers Cancer Institute of New Jersey, New Brunswick, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hiddemann","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, Ludwig-Maximilians University Hospital, Campus Grosshadern, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Marcus","sequence":"additional","affiliation":[{"name":"Department of Haematology, Addenbrookes Hospital, Cambridge, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Kimby","sequence":"additional","affiliation":[{"name":"Karolinska Institutet, and Hematology Centre, Karolinska University Hospital, Stockholm, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Herold","sequence":"additional","affiliation":[{"name":"Leiter Onkologisches Zentrum, Nordh\u00e4user Strasse 74 99089 Erfurt, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Sebban","sequence":"additional","affiliation":[{"name":"Centre L\u00e9on B\u00e9rard, Lyon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7651-9189","authenticated-orcid":false,"given":"Emmanuel","family":"Gyan","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cell Therapy, University of Tours, Tours, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Foon","sequence":"additional","affiliation":[{"name":"Celegene Corporation, Summit, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Pharma Development Clinical Oncology, F. Hoffmann-La Roche Ltd., Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7772-2747","authenticated-orcid":false,"given":"Umberto","family":"Vitolo","sequence":"additional","affiliation":[{"name":"Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia-Istituto di Ricovero e Cura a Carattere Scientifico\u00a0(FPO-IRCCS), Torino, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-8666","authenticated-orcid":false,"given":"Gilles A.","family":"Salles","sequence":"additional","affiliation":[{"name":"Memorial Sloan-Kettering Cancer Center, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Shi","sequence":"additional","affiliation":[{"name":"Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Flowers","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, MD Anderson Cancer Center, University of Texas, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2022031715492163000_B1","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JCO.18.00400","article-title":"Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts","volume":"37","author":"Sarkozy","year":"2019","journal-title":"J Clin Oncol."},{"issue":"1","key":"2022031715492163000_B2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2014-04-516815","article-title":"Transformed follicular non-Hodgkin lymphoma","volume":"125","author":"Casulo","year":"2015","journal-title":"Blood."},{"issue":"23","key":"2022031715492163000_B3","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study [published correction appears in J Clin Oncol. 2016;34(12):1430]","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol."},{"issue":"8","key":"2022031715492163000_B4","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","article-title":"Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy","volume":"128","author":"Jurinovic","year":"2016","journal-title":"Blood."},{"issue":"9759","key":"2022031715492163000_B5","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet."},{"issue":"9873","key":"2022031715492163000_B6","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial [published correction appears in Lancet. 2013;381(9873):1184]","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet."},{"issue":"11","key":"2022031715492163000_B7","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/ajh.24492","article-title":"Early event status informs subsequent outcome in newly diagnosed follicular lymphoma","volume":"91","author":"Maurer","year":"2016","journal-title":"Am J Hematol."},{"issue":"4","key":"2022031715492163000_B8","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/nrc.2017.127","article-title":"From genetics to the clinic: a translational perspective on follicular lymphoma","volume":"18","author":"Huet","year":"2018","journal-title":"Nat Rev Cancer."},{"issue":"4","key":"2022031715492163000_B9","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1470-2045(18)30102-5","article-title":"A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts","volume":"19","author":"Huet","year":"2018","journal-title":"Lancet Oncol."},{"issue":"9","key":"2022031715492163000_B10","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol."},{"issue":"30","key":"2022031715492163000_B11","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","article-title":"Baseline metabolic tumor volume predicts outcome in high-tumor-Burden follicular lymphoma: a pooled analysis of three multicenter studies","volume":"34","author":"Meignan","year":"2016","journal-title":"J Clin Oncol."},{"issue":"22","key":"2022031715492163000_B12","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1182\/blood-2017-11-816298","article-title":"Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA\/FIL study","volume":"131","author":"Cottereau","year":"2018","journal-title":"Blood."},{"issue":"14","key":"2022031715492163000_B13","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a\u00a0phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J Clin Oncol."},{"key":"2022031715492163000_B14","article-title":"Phase IIIb randomized study of lenalidomide plus rituximab (R2) followed by maintenance in relapsed\/refractory NHL: analysis of patients with double-refractory or early relapsed follicular lymphoma (FL) [abstract]","volume":"35","author":"A","year":"2017","journal-title":"J Clin Oncol."},{"issue":"8","key":"2022031715492163000_B15","doi-asserted-by":"crossref","first-page":"e429","DOI":"10.1016\/S2352-3026(19)30089-4","article-title":"Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol."},{"issue":"11","key":"2022031715492163000_B16","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med."},{"issue":"35","key":"2022031715492163000_B17","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma [published correction appears in J Clin Oncol. 2018;36(5):521]","volume":"35","author":"Dreyling","year":"2017","journal-title":"J\u00a0Clin Oncol."},{"issue":"11","key":"2022031715492163000_B18","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.18.00915","article-title":"DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma [published correction appears in J Clin Oncol. 2019;37(16):1448]","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol."},{"issue":"26","key":"2022031715492163000_B19","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med."},{"issue":"6","key":"2022031715492163000_B20","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.bbmt.2017.12.771","article-title":"Autologous transplantation in follicular lymphoma with early therapy failure: a National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis","volume":"24","author":"Casulo","year":"2018","journal-title":"Biol Blood Marrow Transplant."},{"issue":"12","key":"2022031715492163000_B21","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1002\/cncr.31374","article-title":"Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure","volume":"124","author":"Smith","year":"2018","journal-title":"Cancer."},{"issue":"9","key":"2022031715492163000_B22","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood.2019000258","article-title":"Frontline therapy with bendamustine and rituximab (BR) in follicular lymphoma: prognosis among patients with progression of disease by 24 months (POD24) is poor with majority having transformed lymphoma [abstract]","volume":"134","author":"Freeman","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2022031715492163000_B23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","article-title":"A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy","volume":"132","author":"Bachy","year":"2018","journal-title":"Blood."}],"updated-by":[{"DOI":"10.1182\/blood.2026035618","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000}}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/11\/1684\/1881984\/bloodbld2020010263.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/11\/1684\/1881984\/bloodbld2020010263.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T14:10:49Z","timestamp":1647526249000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/139\/11\/1684\/477185\/Validation-of-POD24-as-a-robust-early-clinical-end"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,17]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,3,17]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020010263","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,17]]}}}